(function(doc, html, url) {
var widget = doc.createElement("div");
widget.innerHTML = html;
var script = doc.currentScript; // e = a.currentScript;
if (!script) {
var scripts = doc.scripts;
for (var i = 0; i < scripts.length; ++i) {
script = scripts[i];
if (script.src && script.src.indexOf(url) != -1) break;
}
}
script.parentElement.replaceChild(widget, script);
}(document, '
How Bimodal Neuromodulation with Lenire is Setting a New Standard of Care for Tinnitus Patients
What is it about?
This study highlights the real-world success of Lenire by Neuromod, a bimodal neuromodulation tinnitus treatment device. Researchers conducted a retrospective chart review of tinnitus patients treated with Lenire at New York Hearing Doctors (NYHD). Lenire’s treatment method combines audio played through headphones and mild pulses to the tongue to retrain how the brain perceives tinnitus signals. The analysis focused on 104 patients with bothersome tinnitus (moderate or worse) and showed Lenire’s clinical trial success was replicable in an everyday clinical practice.
Why is it important?
Tinnitus impacts 15% of the global adult population. For the millions living with constant ringing, hissing, buzzing and other noise in their ears, this study offers compelling evidence that significant relief is possible in a standard clinical setting using Lenire: ● Exceptional Success: 81.8% of 104 patients with bothersome tinnitus reported clinically meaningful relief after 12-weeks of Lenire. ● Rapid Improvement: 72.6% of these patients reported clinically significant relief from tinnitus after just 6-weeks. ● Meaningful Change: Patients saw an average 23.8-point drop in their Tinnitus Handicap Inventory (THI) score. This is more than three times the accepted minimum point reduction of 7-points on the THI to meet the clinical significance threshold. ● Scalable Consistency: These results almost mirror earlier peer reviewed real-world findings from Alaska Hearing & Tinnitus, proving that Lenire is a scalable, consistently effective tinnitus treatment option across different clinical environments.